Cycloserine

Cycloserine

Clinical data
Pregnancy category	C
ATC code	J04AB01 (WHO)
Identifiers
IUPAC name 4-aminoisoxazolidin-3-one
CAS Number	68-41-7
PubChem CID	401
DrugBank	APRD00894
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C3H6N2O2
Molar mass	102.092 g/mol

WikiDoc Resources for Cycloserine
Articles
Most recent articles on Cycloserine Most cited articles on Cycloserine Review articles on Cycloserine Articles on Cycloserine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cycloserine Images of Cycloserine Photos of Cycloserine Podcasts & MP3s on Cycloserine Videos on Cycloserine
Evidence Based Medicine
Cochrane Collaboration on Cycloserine Bandolier on Cycloserine TRIP on Cycloserine
Clinical Trials
Ongoing Trials on Cycloserine at Clinical Trials.gov Trial results on Cycloserine Clinical Trials on Cycloserine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cycloserine NICE Guidance on Cycloserine NHS PRODIGY Guidance FDA on Cycloserine CDC on Cycloserine
Books
Books on Cycloserine
News
Cycloserine in the news Be alerted to news on Cycloserine News trends on Cycloserine
Commentary
Blogs on Cycloserine
Definitions
Definitions of Cycloserine
Patient Resources / Community
Patient resources on Cycloserine Discussion groups on Cycloserine Patient Handouts on Cycloserine Directions to Hospitals Treating Cycloserine Risk calculators and risk factors for Cycloserine
Healthcare Provider Resources
Symptoms of Cycloserine Causes & Risk Factors for Cycloserine Diagnostic studies for Cycloserine Treatment of Cycloserine
Continuing Medical Education (CME)
CME Programs on Cycloserine
International
Cycloserine en Espanol Cycloserine en Francais
Business
Cycloserine in the Marketplace Patents on Cycloserine
Experimental / Informatics
List of terms related to Cycloserine

Cycloserine is an oral broad spectrum antibiotic effective against tuberculosis, by inhibiting cell wall synthesis of TB bacilli at early stage of peptidoglycan synthesis. For the treatment against tuberculosis, it is classified as a second line drug.

It is also being trialed for treatment of phobias as well as an adjuvant to conventional treatments for depression, obsessive-compulsive disorder and schizophrenia.

The side effects are mainly CNS manifestations i.e. headache, irritability, depression, convulsions. Co-administration of pyridoxine can reduce the incidence of some of the CNS side effects(e.g. convulsions).

These psychotropic responses are related to D-cycloserine's action as a partial agonist of the neuronal NMDA receptor for glutamate and have been examined in implications with sensory-related fear extinction in the amygdala. See Michael Davis, Barbara Rothbaum, Kerry Ressler et al. and their work with PTSD at Emory University's School of Medicine.